

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of: Morishita et al.

Application No. 09/869,475

Filed: October 10, 2001 Confirmation No. 4309

For:

GENE THERAPY FOR DIABETIC

ISCHEMIC DISEASE

Examiner: Brian A. Whiteman

Art Unit: 1635

Attorney Reference No. 6235-59221-01

MAIL STOP RCE COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP RCE, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)

Date Mailed October 6, 2006

<u>PURSUANT TO 37 C.F.R. § 1.97(b)(4)</u>

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing of a first Office action after the filing of a request for continued examination. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 595-5300

Facsimile: (503) 595-5301

Registration No. 47,913

cc: Docketing

SLR:dm 10/06	6/06 6235-5	9221-01 593075.doc MEI	D-A0102P-US	A 44	D14 NI		6235-59221-01	
		Attorney Docket Number						
		Application Number		09/869,475				
INKOR	FATEMENT	Filing Date		October 10, 2001				
		First Named Inventor		Morishita				
007 10		Art Unit		1635				
001 1		Examiner Name		Brian A. Whiteman				
U.S. PATENT DOCUMENTS Copies of the patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.								
Examiner's Initials*	Cite No. (optional)	Number	Publicati	on Date Name		e of Applicant or Patentee		
						· <u>-</u>		
				-				
FOREIGN PATENT DOCUMENTS								
Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date		A	Name of pplicant or Patentee	
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS						
		Denham et al., "Cationic Liposome-Medicated Gene Transfer During Acute Pancreatitis: Tissue Specificity, Duration, and Effects of Acute Inflammation," <i>J. Gastrointest. Surg.</i> 2:95-101 (1998).						
		Denham et al., "Transient Human Gene Therapy, a Novel Cytokine Regulatory Strategy						
		for Experimental Pancreatitis," <i>Ann. Surg. 227</i> :812-820 (1998). Kurata et al., "Recombinant Adenonirus Vectors for Cytokine Gene Therapy in Mice,"						
		J. Allergy Clin. Immunol. 103:S471-S484 (1999).						
		Thornton et al., "Enhanced Collagen Accumulation Following Direct Transfection of the						

	DATE CONSIDERED:
--	---------------------

Comm. 246:654-659 (1998).

111:190-197 (1999).

Inducible Nitric Oxide Synthase Gene in Cutaneous Wounds," Biochem. Biophys. Res.

Vogel, "A Direct In Vivo Approach for Skin Gene Therapy," Proc. Assoc. Am. Physicians

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.